Tandem Diabetes Care Stock
Tandem Diabetes Care, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- John F. Sheridan
- Employees
- 2,500
- Market cap
- $1.1 B
- IPO
- 14/11/2013
Tandem Diabetes Care, Inc. is a medical technology firm specializing in the creation, development, and marketing of solutions for individuals globally who manage insulin-dependent diabetes. Established in 2006, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January…
Company description based on the data provider's company data, AI-assisted, created on 17/10/2026. Not investment advice.
Tandem Diabetes Care stock: price history
1D
-1.7%
1W
+0.8%
1M
-7.4%
6M
-21.2%
YTD
-26.1%
1Y
+6.2%
2Y
-56.7%
5Y
-87.0%
10Y
-75.4%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~69% stronger price swings than usual
Ask the agents about Tandem Diabetes Care
Analyst assessment of Tandem Diabetes Care
PRICE TARGET LOW
US$15.50
CONSENSUS
US$25.39
MEDIAN
US$21.00
PRICE TARGET HIGH
US$45.00
0
STRONG BUY
24
BUY
15
HOLD
0
SELL
0
STRONG SELL
39
TOTAL · Buy
As of: 30/09/2026
Tandem Diabetes Care stock metrics
P/E
-17.49
P/B
8.52
EV/EBITDA
-51.88
RETURN ON EQUITY
-16.2%
NET MARGIN
-8.3%
DEBT/EQUITY
5.67
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.6%
FLOAT SHARES
63,759,144
AVG. DAILY VOLUME (30D)
2,238,060
Insider transactions (SEC)
Gasser Elizabeth Anne
Carpenter Rick
Carpenter Rick
Carpenter Rick
Hansen Shannon Marie
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.7%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Tandem Diabetes Care stock
What does Tandem Diabetes Care do?
Tandem Diabetes Care, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is John F. Sheridan, the company employs around 2,500 people.
The IPO was on 14/11/2013; the stock trades on NASDAQ under the ticker TNDM.
What do analysts say about Tandem Diabetes Care stock?
39 analysts rate the stock, the consensus is Buy (as of 30/09/2026).
The average price target is US$25.39, ranging from US$15.50 to US$45.00, with a median of US$21.00.
This is an external assessment, not a statement by Market Jury.
When does Tandem Diabetes Care report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 69% stronger than usual.
Does Tandem Diabetes Care pay a dividend?
No, Tandem Diabetes Care currently does not pay a dividend.
Which stocks are comparable to Tandem Diabetes Care?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Tandem Diabetes Care stock analyzed?
Clicking "Analyze stock" lets five strategies assess Tandem Diabetes Care against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.